Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Pemetrexed

Pemetrexed (Alimta) 500mg/\^2 administered intravenously over approximately 10-minutes on Day 1 of a 21-day cycle x 3 cycles

RADIATION

Radiation Therapy

"Radiation will start between days -1 to 2 from day 1 of cycle 1. Day 1 radiotherapy must be a Monday, Tuesday, or Wednesday.~The planned radiation dose is 60 Gy in 2.0 Gy fractions. The entire PTV, including primary tumor and areas of known nodal disease, shall receive 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks."

Trial Locations (18)

19046

Fox Chase Cancer Center Extramural Research Program, Rockledge

19106

Pennsylvania Oncology-Hematology Associates, Philadelphia

46202

IN Onc/Hem Associates, Indianapolis

Indiana University Simon Cancer Center, Indianapolis

46256

Community Regional Cancer Center, Indianapolis

46321

Monroe Medical Associates, Munster

46601

Northern Indiana Cancer Research Consortium, South Bend

46815

Fort Wayne Oncology & Hematology, Inc, Fort Wayne

47303

Medical Consultants, P.C., Muncie

47403

Cancer Care Center of Southern Indiana, Bloomington

47802

Providence Medical Group, Terre Haute

47905

Horizon Oncology Center, Lafayette

60201

NorthShore University Health System - Kellogg Cancer Center, Evanston

60611

Northwestern University Feinberg School of Medicine, Chicago

61401

Medical & Surgical Specialists, LLC, Galesburg

63110

Siteman Cancer Center, St Louis

97213

Providence Portland Medical Center, Portland

08060

Hematology Oncology Associates S.J., P.A., Mount Holly

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Hoosier Cancer Research Network

OTHER